You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. A Novel Approach to Purifying iPSC Derived Cell Cultures

    SBC: HocusLocus Inc.            Topic: 200

    DESCRIPTION provided by applicant We are pioneering an RNA based switch technology called structurally interacting RNAs sxRNA which utilizes post transcriptional gene regulation as a reporter for miRNA detection Normally RNA binding proteins RBP associate with a andapos stem loop structure to facilitate translation of an upstream coding region by as much as an order of magnitude It is ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Automated Assessment of Leptomeningeal Collaterals on CT Angiograms

    SBC: Kitware, Inc.            Topic: 108

    DESCRIPTION provided by applicant The primary goal of this study is to develop an automated scoring system of leptomeningeal collaterals based on CT angiography CTA as a quantitative assessment of acute stroke Leptomeningeal collaterals provide an alternate path of blood flow in the setting of a proximal occlusion The presence and effectiveness of leptomeningeal collaterals i e andquot c ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Contraceptive testing for semen availability in male monkeys

    SBC: Eppin Pharma Inc            Topic: NICHD

    DESCRIPTION provided by applicant The global contraceptives market was valued at $ billion in and is expected to grow at a CAGR of from to to reach an estimated value of $ billion in An important high impact driver of this market is the prevalence of unintended pregnancies In the US there are million unintended pregnancies annually through inconsistent or ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Delivery of peptides for inducing voiding associated with neurological retention

    SBC: Dignify Therapeutics LLC            Topic: 102

    DESCRIPTION provided by applicant Neurological conditions such as multiple sclerosis Parkinsonandapos s disease dementia spina bifida diabetes stroke and spinal cord injury SCI can result in loss of voluntary control over bladder and bowel function often producing both incontinence and retention of urine and stools in the same patient This has a profound impact on the mental and phy ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Development and in vitro validation of therapy for mucopolysaccharidosis III

    SBC: Phoenix Nest Inc.            Topic: 105

    DESCRIPTION provided by applicant Sanfilippo disease mucopolysaccharidosis type III MPS III is a devastating neurodegenerative lysosomal storage disorder of childhood for which there is no cure or effective treatment available The fundamental cause of MPS III is an inherited mutation in one of the enzymes required to catabolize heparan sulfate HS a glycosaminoglycan which plays importa ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a high-throughput assay for measuring m6A demethylase activity

    SBC: Base5 Biosciences Inc            Topic: NIDA

    DESCRIPTION provided by applicant N methyladenosine m A was recently discovered to be a widespread base modification present in thousands of mammalian mRNAs In addition to its prevalence throughout the transcriptome researchers have also revealed that m A is a reversible modification suggesting that dynamic regulation of mRNA methylation is a novel and widespread RNA regulatory mechanism ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Development of an Antigen Capture Assay for Babesia microti

    SBC: Biopeptides, Corp            Topic: NIAID

    DESCRIPTION provided by applicant Babesia microti the primary etiologic agent of human babesiosis is a tick borne eukaryotic apicomplexan pathogen that is an increasing threat to the US public health Although B microti is primarily a tick borne pathogen it can be transmitted by transfusion of infected blood Despite the well recognized threat there is no FDA licensed test to screen donor ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD, LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Development of Small Molecules that Enhance the Delivery and the Pharmacological Effects of Oligonucleotides

    SBC: Initos Pharmaceuticals LLC            Topic: 999

    DESCRIPTION provided by applicant Antisense and siRNA oligonucleotides offer the promise of highly precise manipulation of genes involved in disease pathogenesis However despite the investment of enormous resources that promise has been fulfilled to only a limited degree A key impediment to oligonucleotide based therapeutics is the difficulty in delivering these large highly polar molecule ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Electronic Optimization of Stem Cell Derived Human Cardiac Myocytes

    SBC: Cytocybernetics Inc            Topic: NHLBI

    DESCRIPTION provided by applicant As part of the FDA approval process for novel therapeutic drugs safety screening demonstrating that the new drug does not have deleterious effects on the human cardiac action potential is required Healthy human heart cells are not available for such preclinical drug testing There is currently no consensus on the best experimental approach to provide the most ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government